Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518380

— · C

165a2081-7a4c-5783-a2e3-99ca2bc7175a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.260
  • ESTROGEN_RESPONSE_LATE+0.190
  • SPERMATOGENESIS+0.180
  • UV_RESPONSE_UP+0.170
  • CHOLESTEROL_HOMEOSTASIS+0.160
  • OXIDATIVE_PHOSPHORYLATION+0.160
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.150
  • PROTEIN_SECRETION+0.150
  • DNA_REPAIR+0.140
  • MTORC1_SIGNALING+0.140

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.500
  • INTERFERON_GAMMA_RESPONSE-0.460
  • ALLOGRAFT_REJECTION-0.380
  • IL6_JAK_STAT3_SIGNALING-0.320
  • MYC_TARGETS_V2-0.300
  • COMPLEMENT-0.240
  • TNFA_SIGNALING_VIA_NFKB-0.240
  • MYC_TARGETS_V1-0.210
  • INFLAMMATORY_RESPONSE-0.200
  • IL2_STAT5_SIGNALING-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518241
breast-umap@18
—F0.803
2SRR8518245
breast-umap@18
—F0.793
3SRR8518274
breast-umap@18
—C0.782
4SRR25617914
breast-umap@18
—C0.777
59f9dec84-0c2c-4f85-8024-b8fb1de1eb81
colon-landscapes@1
——0.771
6TCGA-2F-A9KQ-01A-11R-A38B-07
bladder-landscape@3
——0.761
7BSR_19_0079_A1_S53
breast-umap@18
—B0.754
8TCGA-AN-A0FV-01A-11R-A00Z-07
breast-umap@18
—C0.729
9TCGA-C8-A3M8-01A-11R-A213-07
breast-umap@18
—B0.725
10TCGA-XF-A9SV-01A-21R-A42T-07
bladder-landscape@3
——0.724

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.260Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.190Idelalisib— uncovered
SPERMATOGENESIS0.180Inavolisib— uncovered
UV_RESPONSE_UP0.170Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.160Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.160Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.150Inavolisib— uncovered
PROTEIN_SECRETION0.150Remibrutinib— uncovered
DNA_REPAIR0.140Idelalisib— uncovered
MTORC1_SIGNALING0.140Inavolisib— uncovered
ADIPOGENESIS0.130Inavolisib— uncovered
COAGULATION0.130Binimetinib— uncovered
TGF_BETA_SIGNALING0.130Inavolisib— uncovered
ANDROGEN_RESPONSE0.110Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.110Idelalisib— uncovered
GLYCOLYSIS0.100Inavolisib— uncovered
P53_PATHWAY0.090Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.080Inavolisib— uncovered
FATTY_ACID_METABOLISM0.080Inavolisib— uncovered